The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women
Open accessAbstract
Cytological cervical screening is rather inefficient because of relatively high proportions of false negative and false positive smears. To evaluate the efficiency of high‐risk human papillomavirus (hrHPV) testing, by GP5+/6+ PCR‐enzyme immunoassay (EIA), in conjunction with cytology (Intervention Group) to that of the classical cytology (Control Group), we initiated the Population Based Screening Study Amsterdam (POBASCAM). POBASCAM is a population‐based randomized controlled trial for implementation of hrHPV testing in cervical screening. The outcome measure is the proportion of histologically confirmed ≥CIN3 lesions in each study arm up to and including the next screening round after 5 years. We present the design, methods and baseline data of POBASCAM. When, in the next 5 years, the follow‐up will be completed, the data obtained will be used in model studies, including a cost‐effectiveness study, to advise the Dutch Ministry of Public Health in deciding whether cervical screening should be based on combined hrHPV and cytology testing instead of cytology alone. Between January 1999 and September 2002, 44,102 women (mean age = 42.8 years; range = 29–61) that participated in the regular Dutch screening program were included in our study. In the Intervention Group the distribution of cytology and hrHPV by cytology class was as follows: normal cytology 96.6% (3.6% hrHPV positive); borderline and mild dyskaryosis (BMD) 2.5% (34.6% hrHPV positive); and moderate dyskaryosis or worse (>BMD) 0.8% (88.3% hrHPV positive), i.e., 0.4% moderate dyskaryosis (82.9% hrHPV positive), 0.3% severe dyskaryosis (92.5% hrHPV positive), 0.1% carcinoma in situ (95.2% hrHPV positive), <0.1% suspected for invasive cancer (hrHPV positive 100.0%). In the Control Group 96.5% of the women had normal cytology, 2.4% BMD and 0.8% >BMD, i.e., 0.4% moderate dyskaryosis, 0.3% severe dyskaryosis, 0.1% carcinoma in situ, <0.1% suspected for invasive cancer. The presence of hrHPV was age‐dependent, decreasing from 12.0% at 29–33 years to 2.4% at 59–61 years. Among women with a positive hrHPV test, the prevalence of BMD was age‐dependent ranging from 20.2% at 29–33 years to 7.8% at 54–58 years. In contrast, the risk of >BMD of 13.7% among women with a positive hrHPV test was not age‐dependent. Our study indicates that large‐scale hrHPV testing by GP5+/6+ PCR‐EIA in the setting of population‐based cervical screening is practically feasible, is accepted by both participating women and general practitioners and yields highly reproducible results. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
Self-citation2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
Wright, Jr. (2002) · JAMA · doi:10.1001/jama.287.16.2120 · Cited by 1,215
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia
Ho, G. Y. F., Burk, R. D., Klein, S., Kadish, A. S., Chang, C. J., Palan, P., Basu, J., Tachezy, R., Lewis, R., & Romney, S. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.18.1365 · Cited by 803
Nobbenhuis, M. A., Walboomers, J. M., Helmerhorst, T. J., Rozendaal, L., Remmink, A. J., Risse, E. K., van der Linden, H. C., Voorhorst, F. J., Kenemans, P., & Meijer, C. J. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12490-x · Cited by 685
Self-citationMeta-analysis of Pap Test Accuracy
Fahey, M. T., Irwig, L., & Macaskill, P. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117485 · Cited by 684
Manos, M. M., Kinney, W. K., Hurley, L. B., Sherman, M. E., Shieh-Ngai, J., Kurman, R. J., Ransley, J. E., Fetterman, B. J., Hartinger, J. S., McIntosh, K. M., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1605 · Cited by 568
Jacobs, M. V., Snijders, P. J., van den Brule, A. J., Helmerhorst, T. J., Meijer, C. J., & Walboomers, J. M. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.791-795.1997 · Cited by 568
Self-citationSchiffman, M., Herrero, R., Hildesheim, A., Sherman, M. E., Bratti, M., Wacholder, S., Alfaro, M., Hutchinson, M., Morales, J., Greenberg, M. D., et al. (2000) · JAMA · doi:10.1001/jama.283.1.87 · Cited by 540
Clavel, C., Masure, M., Bory, J.-P., Putaud, I., Mangeonjean, C., Lorenzato, M., Nazeyrollas, P., Gabriel, R., Quereux, C., & Birembaut, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1845 · Cited by 465
Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.
(2001) · Europe PMC (PubMed Central) · Cited by 463
Kulasingam, S. L., Hughes, J. P., Kiviat, N. B., Mao, C., Weiss, N. S., Kuypers, J. M., & Koutsky, L. A. (2002) · JAMA · doi:10.1001/jama.288.14.1749 · Cited by 452
Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., & Schiffman, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.46 · Cited by 430
Remmink, A. J., Walboomers, J. M. M., Helmerhorst, T. J. M., Voorhorst, F. J., Rozendaal, L., Risse, E. K. J., Meijer, C. J. L. M., & Kenemans, P. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610305 · Cited by 368
Self-citationVizcaino, A. P., Moreno, V., Bosch, F. X., Muñoz, N., Barros-Dios, X. M., & Parkin, D. M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980209)75:4<536::aid-ijc8>3.0.co;2-u · Cited by 316
Petry, K.-U., Menton, S., Menton, M., van Loenen-Frosch, F., de Carvalho Gomes, H., Holz, B., Schopp, B., Garbrecht-Buettner, S., Davies, P., Boehmer, G., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600918 · Cited by 300
International trends in incidence of cervical cancer: II. Squamous-cell carcinoma
Vizcaino, A. P., Moreno, V., Bosch, F. X., Mu�oz, N., Barros-Dios, X. M., Borras, J., & Parkin, D. M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000501)86:3<429::aid-ijc20>3.0.co;2-d · Cited by 285
HPV testing in primary screening of older women
Cuzick, J., Beverley, E., Ho, L., Terry, G., Sapper, H., Mielzynska, I., Lorincz, A., Chan, W.-K., Krausz, T., & Soutter, P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690730 · Cited by 268
Schiffman, M., & Adrianza, E. (2000) · Acta Cytologica · doi:10.1159/000328554 · Cited by 252
Human papillomavirus testing for primary screening of cervical cancer precursors.
Ratnam, S., Franco, E. L., & Ferenczy, A. S. (2000) · PubMed · Cited by 240
Nobbenhuis, M. A., Helmerhorst, T. J., van den Brule, A. J., Rozendaal, L., Voorhorst, F. J., Bezemer, P. D., Verheijen, R. H., & Meijer, C. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06809-x · Cited by 227
Self-citationSchneider, A., Hoyer, H., Lotz, B., Leistritza, S., Kühne-Heid, R., Nindl, I., Müller, B., Haerting, J., & Dürst, M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<529::aid-ijc11>3.0.co;2-g · Cited by 222
Trends in cancer of the cervix uteri in Sweden following cytological screening
Bergström, R., Sparén, P., & Adami, H.-O. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690666 · Cited by 220
Human Papillomavirus DNA Testing as an Adjunct to Cytology in Cervical Screening Programs
Lörincz, A. T., & Richart, R. M. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-959-hpdtaa · Cited by 182
Bulk, S., van Kemenade, F. J., Rozendaal, L., & Meijer, C. J. L. M. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011841 · Cited by 142
Self-citationHuman papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Sigurdsson, K. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540408 · Cited by 124
van Ballegooijen, M., Marle, M. E. V. D. A., Patnick, J., Lynge, E., Arbyn, M., Anttila, A., Ronco, G., Dik, J.-W. H., & Habbema, F. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00330-0 · Cited by 118
Rozendaal, L., Westerga, J., van der Linden, J. C., Walboomers, J. M. M., Voorhorst, F. J., Risse, E. K. J., Boon, M. E., & Meijer, C. J. L. M. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.8.606 · Cited by 98
Self-citationZielinski, G. D., Snijders, P. J. F., Rozendaal, L., Voorhorst, F. J., Runsink, A. P., de Schipper, F. A., & Meijer, C. J. L. M. (2001) · The Journal of Pathology · doi:10.1002/path.981 · Cited by 85
Self-citationCriteria for Organized Cervical Screening Programs
Hanselaar, A. G. J. M. (2002) · Acta Cytologica · doi:10.1159/000326965 · Cited by 80
Cervical cancer screening in The Netherlands
van Ballegooijen, M., & Hermens, R. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00317-8 · Cited by 74
Cited by
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Self-citationde Sanjosé, S., Diaz, M., Castellsagué, X., Clifford, G., Bruni, L., Muñoz, N., & Bosch, F. X. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70158-5 · Cited by 1,669
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.10897 · Cited by 1,409
Cuzick, J., Clavel, C., Petry, K., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21955 · Cited by 1,141
Self-citationHuman Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073204 · Cited by 797
Metadata
- Authors
- Bulkmans, N. W. J., Rozendaal, L., Snijders, P. J. F., Voorhorst, F. J., Boeke, A. J. P., Zandwijken, G. R. J., van Kemenade, F. J., Verheijen, R. H. M., v Groningen, K., Boon, M. E., Keuning, H. J. F., van Ballegooijen, M., van den Brule, A. J. C., & Meijer, C. J. L. M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-02-09
- Volume
- 110
- Issue
- 1
- Pages
- 94-101
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2009256930
- Cited by
- 269
- References
- 32
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.